FiercePharma

Vimpat® (lacosamide) provided sustained efficacy and good tolerability for up to 8 years in patients with partial onset seizures

Long term data from four open label lacosamide extension trials reported at the 29th International Epilepsy Congress New non-interventional study (VITOBA TM) aims to investigate additive or ...
Monthly Prescribing Reference

Motpoly XR, a Once-Daily Formulation of Lacosamide, Now Available

Motpoly XR is bioequivalent to Vimpat (lacosamide) film-coated tablets and provides a new once-daily option at equivalent doses. Motpoly XR™ (lacosamide) extended-release capsules are now available ...
EurekAlert!

New data for Vimpat (lacosamide) C-V showed sustained efficacy for up to 5 years

ATLANTA, June 29, 2010 /EurekAlert!/ — New long term data showed that Vimpat® (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment ...
Nasdaq

UCB's VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy

-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...
FierceBiotech

UCB Group Receives Not-approvable Letter from FDA for Lacosamide for Diabetic Neuropathic Pain

BRUSSELS, BELGIUM--(Marketwire - July 29, 2008) - 6 pm CEST - press release, regulated information: UCB announced today that it received a not-approvable letter from the U.S. Food and Drug ...
Medscape

Long-Term Results Show Lacosamide Continues to Reduce Seizures

December 8, 2010 — Results from a phase 3 open-label extension study show adjunctive lacosamide reduces partial-onset seizures long term. "These data add to the growing body of support showing that ...
Monthly Prescribing Reference

Vimpat Oral Solution

Lacosamide 10mg/mL; strawberry-flavored; contains phenylalanine 0.32mg/20mL. The precise mechanism by which Vimpat exerts its antiepileptic effects in humans remains to be fully elucidated. In vitro ...
Medscape

FDA Okays Lacosamide Monotherapy in Partial-Onset Seizures

The US Food and Drug Administration (FDA) has approved a supplemental new drug application for the antiepileptic drug lacosamide (Vimpat, UCB) as monotherapy in treating partial-onset seizures in ...
FierceBiotech

New Data on Vimpat® (lacosamide) C-V to be Presented at the 64th Annual Meeting of the American Epilepsy Society

ATLANTA, Nov. 30, 2010 /PRNewswire/ -- New data on UCB's anti-epileptic drug (AED) Vimpat® (lacosamide) C-V will be presented at the 64th annual meeting of the American Epilepsy Society (AES), taking ...
EurekAlert!

Multiple Vimpat (lacosamide) studies presented at American Epilepsy Society Annual Meeting

UCB today announced new findings from analyses of pooled Vimpat(r) (lacosamide) clinical trial data, demonstrating that the new antiepileptic drug (AED) starts working during the first week of ...
News Medical

Vimpat Tablets and Oral Solution

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Do not use if you have ever had an allergic reaction to lacosamide or ...